Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone

Abstract Background X-linked hypophosphatemia (XLH) is characterized by increased serum concentrations of fibroblast growth factor 23 (FGF23), hypophosphatemia and insufficient endogenous synthesis of calcitriol. Beside rickets, odonto- and osteomalacia, disproportionate short stature is seen in mos...

Full description

Bibliographic Details
Main Authors: Diana-Alexandra Ertl, Justin Le Lorier, Andreas Gleiss, Séverine Trabado, Candace Bensignor, Christelle Audrain, Volha Zhukouskaya, Régis Coutant, Jugurtha Berkenou, Anya Rothenbuhler, Gabriele Haeusler, Agnès Linglart
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Orphanet Journal of Rare Diseases
Subjects:
X-linked hypophosphatemia (XLH)
Burosumab
Growth
Recombinant human growth hormone
Children
Online Access:https://doi.org/10.1186/s13023-022-02562-9

Internet

https://doi.org/10.1186/s13023-022-02562-9

Similar Items